These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 20132557)

  • 41. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
    Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
    J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Huang W; Fan M; Liu B; Fu Z; Zhou T; Zhang Z; Gong H; Li B
    J Nucl Med; 2014 Oct; 55(10):1584-90. PubMed ID: 25214640
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by
    Mazzola R; Fiorentino A; Di Paola G; Giaj Levra N; Ricchetti F; Fersino S; Tebano U; Pasetto S; Ruggieri R; Salgarello M; Alongi F
    J Thorac Oncol; 2017 Mar; 12(3):547-555. PubMed ID: 28126325
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning.
    Coon D; Gokhale AS; Burton SA; Heron DE; Ozhasoglu C; Christie N
    Clin Lung Cancer; 2008 Jul; 9(4):217-21. PubMed ID: 18650169
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Invasive Nodal Staging via Endobronchial Ultrasound and Outcome in Patients Treated with Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer - Results from a Single Institution Study.
    George B; Baydoun A; Bhat S; Bailey L; Arsenault T; Sun Y; Zhang Y; Zheng Y; Vempati P; Podder T; Biswas T
    Clin Lung Cancer; 2024 Jun; 25(4):e181-e188. PubMed ID: 38553326
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prognostic factors in non-small cell lung cancer patients and prognostic importance of PET/CT SUV max value].
    Erdem V; Selimoğlu Şen H; Kömek H; Tanrikulu AC; Abakay A; Sezgi C; Kaya H; Senyiğit A
    Tuberk Toraks; 2012; 60(3):207-17. PubMed ID: 23030745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.
    Nestle U; Kremp S; Schaefer-Schuler A; Sebastian-Welsch C; Hellwig D; Rübe C; Kirsch CM
    J Nucl Med; 2005 Aug; 46(8):1342-8. PubMed ID: 16085592
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
    Chang JY; Liu H; Balter P; Komaki R; Liao Z; Welsh J; Mehran RJ; Roth JA; Swisher SG
    Radiat Oncol; 2012 Sep; 7():152. PubMed ID: 22963661
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.
    Taremi M; Hope A; Dahele M; Pearson S; Fung S; Purdie T; Brade A; Cho J; Sun A; Bissonnette JP; Bezjak A
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):967-73. PubMed ID: 21377293
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 18F-FDG PET-CT: predicting recurrence in patients following percutaneous cryoablation treatment for stage I primary non-small-cell lung cancer.
    LoGiurato B; Matthews R; Safaie E; Moore W; Bilfinger T; Relan N; Franceschi D
    Nucl Med Commun; 2015 Sep; 36(9):908-13. PubMed ID: 25973693
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.
    Berghmans T; Dusart M; Paesmans M; Hossein-Foucher C; Buvat I; Castaigne C; Scherpereel A; Mascaux C; Moreau M; Roelandts M; Alard S; Meert AP; Patz EF; Lafitte JJ; Sculier JP;
    J Thorac Oncol; 2008 Jan; 3(1):6-12. PubMed ID: 18166834
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases.
    Stinauer MA; Diot Q; Westerly DC; Schefter TE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e613-8. PubMed ID: 22494588
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.
    Zhang ZJ; Chen JH; Meng L; Du JJ; Zhang L; Liu Y; Dai HH
    Chin Med J (Engl); 2007 Jan; 120(2):125-31. PubMed ID: 17335654
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases.
    Al-Sarraf N; Gately K; Lucey J; Aziz R; Doddakula K; Wilson L; McGovern E; Young V
    Eur J Cardiothorac Surg; 2008 Oct; 34(4):892-7. PubMed ID: 18722132
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of stereotactic body radiation therapy for biopsy-proven versus radiographically diagnosed early-stage non-small lung cancer: a single-institution experience.
    Fischer-Valuck BW; Boggs H; Katz S; Durci M; Acharya S; Rosen LR
    Tumori; 2015; 101(3):287-93. PubMed ID: 25908031
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Defining a radiotherapy target with positron emission tomography.
    Black QC; Grills IS; Kestin LL; Wong CY; Wong JW; Martinez AA; Yan D
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1272-82. PubMed ID: 15519800
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
    Lee JW; Na JO; Kang DY; Lee SY; Lee SM
    Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.